Last reviewed · How we verify
Natrecor (NESIRITIDE)
At a glance
| Generic name | NESIRITIDE |
|---|---|
| Sponsor | Scios Llc |
| Drug class | Natriuretic Peptide |
| Target | Atrial natriuretic peptide receptor 1 |
| Modality | Recombinant protein |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
| First approval | 2001 |
Approved indications
- Decompensated cardiac failure
- Decompensated chronic heart failure
Common side effects
Key clinical trials
- A Study of Ponsegromab in People With Heart Failure (PHASE2)
- The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination
- Prospective Evaluation of AI-ECG for SHD Detection
- Boston Medical Center Ultrasound Decongestion Study in Heart Failure (NA)
- Study of ALXN2220 Versus Placebo in Adults With ATTR-CM (PHASE3)
- Hospital Register of Decompensated Heart Failure With Preserved Ejection Fraction
- Targeted Assessment in High-Risk paTients With dIAbetes to ideNtify Undiagnosed Heart Failure (NA)
- REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Natrecor CI brief — competitive landscape report
- Natrecor updates RSS · CI watch RSS
- Scios Llc portfolio CI